### Informatics as a tool for antimicrobial stewardship

### Guillaume Béraud

Université Laval, Canada

October 5th, 2017



- 2 Computerized decision support system
- 3 A source for Big Data

# The problem : When to start / When to stop

- Diagnosis are difficult & Mistakes are costly !
- Fever : Bacterial vs. viral? Cancer? Embolism? ...
- The cure of an infection is very difficult to assess :
  - A patient may be cure if no relapse occurs in absence of antibiotics after a certain duration (may be years for bone infections!)
- In other words, we don't know much ...
- ullet  $\Rightarrow$  Need of surrogates for diagnosis of infection and cure :
  - Computerized decision support system are potentially helpful surrogates

# What is it

• A program that generates diagnostic and therapeutic recommendations from patient specific information that was input about the suspected diagnosis, such as the presence or absence of specific signs and symptoms

What

- "Medical artificial intelligence"
- A system that links all the information available in various databases (clinical files, laboratory results, pharmacist...)

# Problem

- Many different systems operating in parallel in hospital
- Not standardized
- Not communicating



What How Why

Toward a common language for interoperability : HL7





Guillaume Béraud Informatics & AMS

## Not that recent

- Electronically identified interventions<sup>1</sup>
- LDS Hospital in Salt Lake City, Utah
- 545 patients in a 12-beds ICU over 1 year
- Outcomes compared to 2 previous years
- $\searrow$  in inappropriate ATB doses, ATB related drug events and total cost of care . . .

How

What How Why

# Effective even if basic

IHC ANTIBIOTIC ASSISTANT & ORDER PROGRAM								
00000000 Doe, John O. E	615 77vr M	Dx:PANCR	EATITIS					
Max 24hr WBC = $26.3 \pm (21.1)$ Admit: $\frac{106}{21}$ Admit: $\frac{106}{21}$ Max 24hr Temp = $38.3 \pm (37.8)$								
RENAL FUNCTION: Impaired, $CrCl= 28$ , Max 24hr $Cr=2.0 \downarrow$ (2.2) IBW: 77kg								
Patient's Diff shows a left shift, Max 24hr Bands = 20 1 (8)								
ANTIBIOTIC ALLERGIE	S: Ofloxacin							
CURRENT ANTIBIOTICS	:							
1. 07/14/96.17:23 AMPHOTERICIN B, VIAL 45 Q 24hrs								
2. 07/18/96.12:19 VANCO	MYCIN (VAN	COCIN), VIAI	1000	Q 72hrs				
Total amphotericin given =	181mg							
<b>IDENTIFIED PATHOGEN</b>	S	SITE	COI	LECTED				
Enterococcus T-		T-Tube	07/1	7/96.10:57				
Staphylococcus aureus		Blood	07/1	7/96.10:28				
Candida albicans		Abdomen	07/14/96.06:23					
ABX SUGGESTION	DOSAGE	ROUTE	INTERVA	INTERVAL				
Vancomycin	*1000mg	IV	*q72h	(infuse over 1hr)				
Amphotericin B	45mg	IV	q24h	(infuse over 2-4hr)				
Suggested Antibiotic Duration: 28 days								
* Adjusted based on patier	nt's renal funct	ion						
<1>Micro, <2>Organisa	mSuscept, <3>	> Drug Info, <-	4 > Explain	Logic, <5>Empiric Abx				
<6>Abx Hx, <7>ID Rnds, <8>Lab/Abx Levels, <9>Xray, <+ or F12>Change Patient								
<esc>EXIT, <f1>Help, &lt;0&gt;User Input, &lt;.&gt;OutpatientModels</f1></esc>								
ORDERS: <*> Suggested Abx, <enter> Abx List,  D/C Abx, &lt;-&gt; Modify Abx</enter>								

注▶ 注

- What How Why
- 14 minutes vs. 3.5 seconds<sup>2</sup>
- Decreased cost <sup>3</sup>
- Appropriate antibiotic choice <sup>4</sup>
- Fewer antibiotic doses <sup>5</sup>
- Shorter LOS<sup>6</sup>
- Decreased adverse events<sup>7</sup>
- Decreased mortality<sup>8</sup>
- 2. Evans RS. NEJM 1998

3. Evans RS. *NEJM* 1998, Barenfanger J *J Clin Microbiol* 2001, Jozefiak ET *Am J Health Syst Pharm* 1995, McGregor JC *J Am Med Inform Assoc* 2006, Paul M *JAC* 2006, Pestotnik SL *Ann Intern Med* 1996, Schentag JJ *Diagn Microbiol Infec Dis* 1993

4. Paul M JAC 2006, Samore MH JAMA 2005, Thursky KA Int J Qual Health care 2006

- 5. Evans RS. NEJM 1998, Pestotnik SL Ann Intern Med 1996
- 6. Evans RS. NEJM 1998, Paul M JAC 2006
- 7. Evans RS. NEJM 1998, Pestotnik SL Ann Intern Med 1996
- 8. Pestotnik SL Ann Intern Med 1996

What How Why

### Classical commercial systems with AMS options

Product Name	Company (also known as)	City, State	Infection Prevention Capabilities	
360 Care Insights	Truven	Ann Arbor, MI	Yes	
ABX Alert	ICNet	Warrensville, IN	Yes	
Antibiotic Assistant	Hospira (Theradoc)	Salt Lake City, UT	Yes	
Dynamic Monitoring Suite	Vigilanz	Minneapolis, MN	Yes	
Epiquest Live	Epiquest Live	Boca Raton,FL	Yes	
Medici	Asolva Inc	Pasadena, CA	Yes	
Patient Event Advisor	Care Fusion (Medmined)	Birmingham, AL	Yes	
QC Pathfinder	Vecna	Cambridge, MA	Yes	
Safety Advisor	Premier	Charlotte, NC	Yes	
Sentri 7	Wolters Kluwer (Pharmacy One Source)	Bellevue, WA	Yes	

< 一型

What How Why

# And very sophisticated ones



イロト イポト イヨト イヨト

Guillaume Béraud Informatics & AMS

## Common alerts for infectious diseases

- Bug-Drug mismatch
- Positive culture but no antibiotic
- Antibiotic but no positive culture
- IV to PO
- Duration of therapy alerts
- Duplicate antibiotic therapy
- Dose adjustments to renal/liver function
- Target specific antibiotics (carbapenem, costly ATB ...)

What

Why

• Target organism (MDRO)

# Practical examples

- Patients under Vancomycin >72h without positive culture
- Patients receiving Piperacillin/Tazobactam and Metronidazole

What

Why

- Patients eligible for conversion from IV to PO linezolid
- Levofloxacin at full dose with renal insufficiency
- Positive blood culture for C. albicans and no antifungal treatment

But it is also beneficial for non ID-related problems (anticoagulation...)

## Outpatient example

- Three arm cluster randomized trial <sup>9</sup>
- 33 primary care practices in Pennsylvania, USA
- Acute uncomplicated bronchitis
- Control vs. Print Based vs. Decision support

Guillaume Béraud

What How Why



Guillaume Béraud Informatics & AMS

э

What How Why

#### EVIDENCE-BASED MANAGEMENT OF ACUTE RESPIRATORY TRACT INFECTIONS



Guillaume Béraud Informatics & AMS

Wha How Why

## Results on antibiotic prescribing

- Control arm :  $\nearrow$  (72.5% $\rightarrow$ 74.3%)
- Print-based arm :  $\searrow$  (80% $\rightarrow$ 68.3%)
- Computerized decision support arm :  $\searrow \searrow$  (74.0% $\rightarrow$ 60.7%)



• • • • • • • • •

э

æ

What How Why

# Additional benefits with CDSS

CDSS similarly efficient to printed-based support, but

- Reports can be edited easily
- A general tool that can be easily adapted for many situation, according to new guidelines, new intervention ...
- Adherence can be measured (useful to justify your AMS Team)

What How Why

# Collaboration through CDSS

- Multisite ASP implementation supported by central CDSS
- Five Australian hospitals, 2010-2014
- Bond S. et al, JAC 2017

		ntroduc	tion of a m ASP across	ultisite CD 12 hospital	5S-supported sites		
Included	in study evaluation				Excluded	from stu	dy evaluation
Hospital	Beds/ type	CDSS implementation			Ward roun	ds	
		E	ducation	Go-lin	2		
St George†	650/ metro tertiary	Oct 11-Apr 12		May 2012	Daily Mon-F	ri	
Wollongong	550/ regional tertiary	Oct	11-May 12	May 2012	Daily Mon-F	ri	
Shellharbour	100/ regional general	Oct	11-May 12	May 2012	Twice week	v	
Shoalhaven	150/ regional referral	Oct	Oct 11-May 12 Ma		Twice week	v	
Prince of Wales	550/ metro tertiary	Oct	11-Jul 12	Jul 2012	Daily Mon-F	ri	
			Hose	oitel	Beds/ type		Exclusion*
			Sydney/Sydney Eve		80/metro specialist		Dalayad
Common interventions across included sites			Sutherland 400 Sydney Children's 154		400/ metro referra	)/ metro referral	
					150/ specialist paediatric		Data not
			Royal Women's		150/ metro specialist		comparable
			Bulli Port Kembla Milton-Ulladulla		50/ regional subac	/regional subacute /regional subacute /rural general	
					70/ regional subac		
					30/ rural general		

- Consensus antimicrobial guideline development with traffic light system: green unrestricted; yellow –
  restricted with approval required through CDSS 24/7; red ID/microbiologist pre-authorisation approval only
- Development of CDSS clinical content to support consensus guidelines, agreed at monthly teleconferences
- Removal of restricted antimicrobials from ward stock (general wards)
- Resource development: lanyard card empiric antimicrobial guidelines; A4 posters (eg. surgical prophylaxis, community-acquired pneumonia); hospital intranet website (eg. aminoglycoside and vancomycin dosing guides; antifungal guidelines, CDSS process and contacts; FAQ)
- CDSS on-site training for all medical officers and pharmacists, annually and as required
- Promotion, educational material, hospital grand round and departmental presentations
- Ward rounds (ID doctor and pharmacist) 2-5 days per week with post-prescription review and feedback
- Bimonthly antimicrobial usage audit and national benchmarking with National Antimicrobial Utilization Surveillance Program (NAUSP) reported to each facility Antimicrobial Stewardship Committee for review Monitoring of Clostridum difficie cases

What How Why

### Interrupted Time Series

- Antibiotics targeted to decrease (+32%, p<0.01)
   </li>
- Antibiotics targeted to increase (-23%, p<0.01)
   </li>
- No increase in length of stay or mortality
- But influence decreased over time
- $oldsymbol{0} \Rightarrow \mathsf{An}$  efficient tool
- Ø But just a tool
- which won't replace the AMS team



# A source for Big Data

- Data mining on the gathered information
- New patterns to be discovered
- Which will results in new algorithms to feed the AI



# If you want to implement a CDSS

### Oetermine your objectives (and take your time)

- information needs
- gap within your current digital tools
- workflow interruptions requiring manual intervention
- . . .
- Choose a modular system (the tool should be adapted to your needs, you shouldn't need to adapt)
- Implement a system with option for Big Data tools (e.g. CARD)

# **Bioinformatics for AMS**

- Comprehensive Antibiotic Resistance Database (CARD; arpcard.mcmaster.ca)
- $\bullet\,$  From phenotype of resistance to genotype ightarrow data collection
- $\bullet\,$  From genotype to prediicting phenotype  $\to$  an AMS tool



### Tools



< □ > <

Thank you for your attention



### Whatever you do, your kids will be geek

